denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: independent educational grants from Bristol Myers Squibb, Geron, GSK, and CTI BioPharma Corp., a Sobi Company.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Education, Diseases, Treatment Considerations, Adverse Events, Biological Processes
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Clinical Practice (Health Services and Quality), Plasma Cell Disorders, Education, Diseases, Treatment Considerations, Adverse Events, Biological Processes
Friday, December 6, 2024: 7:00 AM-10:00 AM
Pacific Ballroom Salons 18-19
(Marriott Marquis San Diego Marina)
Chair:
Professor Claire Harrison, Guy's and St Thomas' NHS Foundation Trust
Disclosures:
Harrison: CTI BioPharma: Consultancy, Ended employment in the past 24 months, Honoraria; Incyte: Consultancy, Honoraria, Other: Teaching and Speaking; Research: PI, Speakers Bureau; AbbVie: Consultancy, Honoraria, Other: Teaching and speaking; Research: PI, Speakers Bureau; IMAGO: Consultancy, Honoraria, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; AOP: Consultancy, Honoraria, Speakers Bureau; MorphoSys/Constellation: Consultancy, Honoraria, Other: Research: PI, Research Funding, Speakers Bureau; GSK: Consultancy, Honoraria, Other: Teaching and speaking; Research: PI, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Other: Teaching and speaking; Research: PI, Research Funding, Speakers Bureau; Keros: Consultancy, Honoraria, Speakers Bureau; Galecto: Consultancy, Honoraria; Geron: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; MSD: Consultancy, Honoraria, Speakers Bureau; Sobi: Consultancy; Roche: Consultancy, Honoraria; Promedior: Honoraria; EHA: Other: Leadership role; MPN voice: Other: Leadership role.
Speakers:
Catriona Jamieson, MD, PhD, Sanford Stem Cell Institute, CIRM UC San Diego Alpha Stem Cell Clinic
and
Professor Francesco Passamonti, MD, University of Milano
Disclosures:
No relevant conflicts of interest to declare.
This CME/MOC/AAPA activity is provided by PVI, PeerView Institute for Medical Education and developed with our educational partner, the HealthTree Foundation for Myelofibrosis.
In collaboration with, HealthTree Foundation for Myelofibrosis, PeerView’s Seminars & Workshop educational design will combine real-world cases with scientific evidence to demonstrate modern principles of treatment individualization with JAKi platforms, while also preparing the audience for the emergence of newer, innovative therapeutics targeting unique aspects of MF biology. Throughout, a panel of leading experts in myelofibrosis will illustrate:
- The role of JAKi or the upfront and sequential management of higher-risk MF, as an alternative or support to HCT
- Treatment goals when selecting newer JAKi for MF with anemia or thrombocytopenia
- The potential of investigational approaches and unique MOAs when addressing MF complications (including anemia)
- Strategies to elevate patient outcomes when using JAKi therapy or when addressing the challenges of pretreated MF—including with unique MOAs that can be used as add-on or sequential therapy.
This activity will equip learners with the skills to master the modern science of MF care, and offer enhanced outcomes to patients.
See more of: Friday Satellite Symposia